Lexicon Pharma (LXRX) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.08 +2.97%
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $2.92 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS sees a negative catalyst ahead for Nike: Here’s what to watch
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Paradium AI (PAAI) Halted, News Pending
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
